GlassScriptPhysician profile
Rajiv Anand
NPI 1508865254
$2,499.77
in general payments reported to CMS, 2019-2025
19 companies · $39.48 in 2025
The $39.48 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $648 · 2020: $67.09 · 2021: $171 · 2022: $324 · 2023: $428 · 2024: $822 · 2025: $39.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,049 · Travel and Lodging: $241.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,048.55 |
| Travel and Lodging | $241.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $500.00 | 2019 | |
| Alcon Vision LLC | $477.72 | 2021-2024 | |
| Alimera Sciences, INC. | $251.89 | 2020-2024 | Iluvien, Yutiq |
| Novartis Pharmaceuticals Corporation | $218.25 | 2019-2022 | |
| Horizon Therapeutics Plc | $159.72 | 2020-2023 | Tepezza |
| Genentech USA, INC. | $153.53 | 2022-2024 | Vabysmo |
| Coherus Oncology, INC. | $126.17 | 2023 | |
| Carl Zeiss Meditec USA, INC. | $85.90 | 2021-2025 | |
| Allergan, INC. | $82.84 | 2019-2021 | |
| Amgen INC. | $79.14 | 2024 | Tepezza |
| Abbvie INC. | $65.77 | 2022-2024 | |
| Apellis Pharmaceuticals, INC. | $62.97 | 2023 | Syfovre |
| Sandoz INC. | $58.46 | 2024 | Cimerli |
| Regeneron Healthcare Solutions, INC. | $46.42 | 2019-2023 | Eylea |
| Mallinckrodt Hospital Products INC. | $34.36 | 2021 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $32.32 | 2024 | Izervay |
| Oculus Surgical INC. | $24.06 | 2021 | |
| Bausch & Lomb Americas INC. | $22.62 | 2022 | |
| Biogen, INC. | $17.63 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rajiv Anand listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.